We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.
- Authors
Turnbull, James; Jha, Rakesh R; Ortori, Catherine A; Lunt, Eleanor; Tighe, Patrick J; Irving, William L; Gohir, Sameer A; Kim, Dong-Hyun; Valdes, Ana M; Tarr, Alexander W; Barrett, David A; Chapman, Victoria
- Abstract
<bold>Background: </bold>Specialized proresolution molecules (SPMs) halt the transition to chronic pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-inflammatory bioactive lipids in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients, and to identify potential relationships with innate responses and clinical outcome.<bold>Methods: </bold>Serum from 50 hospital admitted inpatients (22 female, 28 male) with confirmed symptomatic SARS-CoV-2 infection and 94 age- and sex-matched controls collected prior to the pandemic (SARS-CoV-2 negative), were processed for quantification of bioactive lipids and anti-nucleocapsid and anti-spike quantitative binding assays.<bold>Results: </bold>SARS-CoV-2 serum had significantly higher concentrations of omega-6-derived proinflammatory lipids and omega-6- and omega-3-derived SPMs, compared to the age- and sex-matched SARS-CoV-2-negative group, which were not markedly altered by age or sex. There were significant positive correlations between SPMs, proinflammatory bioactive lipids, and anti-spike antibody binding. Levels of some SPMs were significantly higher in patients with an anti-spike antibody value >0.5. Levels of linoleic acid and 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid were significantly lower in SARS-CoV-2 patients who died.<bold>Conclusions: </bold>SARS-CoV-2 infection was associated with increased levels of SPMs and other pro- and anti-inflammatory bioactive lipids, supporting the future investigation of the underlying enzymatic pathways, which may inform the development of novel treatments.
- Publication
Journal of Infectious Diseases, 2022, Vol 225, Issue 12, p2142
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiab632